Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies Journal Article


Authors: Davila, M. L.; Bouhassira, D.; Park, J. H.; Curran, K. J.; Smith, E.; Pegram, H. J.; Brentjens, R.
Article Title: Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
Abstract: The genetic modification of autologous T cells with chimeric antigen receptors (CARs) represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies. By targeting the CD19 antigen, we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic leukemia (B-ALL). We demonstrated rapid induction of deep molecular remissions in adults, which has been recently confirmed in a case report involving a child with B-ALL. In contrast to the results when treating B-ALL, outcomes have been more modest in patients with chronic lymphocytic leukemia (CLL) or other non-hodgkin's lymphoma (NHL). We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL. Lastly, we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple myeloma and acute myeloid leukemia. We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies. © 2013 The Japanese Society of Hematology.
Keywords: hematologic malignancies; car; adoptive t cell therapy
Journal Title: International Journal of Hematology
Volume: 99
Issue: 4
ISSN: 0925-5710
Publisher: Springer Japan KK  
Date Published: 2014-04-01
Start Page: 361
End Page: 371
Language: English
DOI: 10.1007/s12185-013-1479-5
PROVIDER: scopus
PUBMED: 24311149
PMCID: PMC4684946
DOI/URL:
Notes: Int. J. Hematol. -- Cited By (since 1996):1 -- Export Date: 2 June 2014 -- CODEN: IJHEE -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Kevin Joseph Curran
    144 Curran
  3. Jae Hong Park
    356 Park
  4. Marco Luis Davila
    24 Davila
  5. Hollie Jaine Pegram
    19 Pegram
  6. Eric Smith
    76 Smith